Brian Chudik, DO
Family Medicine · Algonquin, ILNPI 1376541763
Payments from drug & device makers
Across 63 payments — averaging $44.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$648
- Novo Nordisk$452
- Lilly USA, LLC$437
- Johnson & Johnson$415
- Edwards Lifesciences$317
- Abbott$196
- plus $364 from 9 others
What the payments were for
- Food & beverage$2,829100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $648 |
| Novo Nordisk | 9 | $452 |
| Lilly USA, LLC | 22 | $437 |
| Johnson & Johnson | 7 | $415 |
| Edwards Lifesciences | 3 | $317 |
| Abbott | 4 | $196 |
| Medtronic | 1 | $110 |
| GSK | 4 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $48 |
| Dexcom, Inc. | 1 | $35 |
| Pfizer | 1 | $27 |
| Baxter Healthcare | 1 | $26 |
| Surmodics, Inc. | 1 | $20 |
| Amgen | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$549
- XARELTO$218
- SAPIEN 3 Ultra RESILIA$172
- CARDIOMEMS$136
- ZEPBOUND$122
- Ozempic$120
- MOUNJARO$113
- Edwards SAPIEN 3 Transcatheter Heart Valve$108
- SPRAVATO$106
How this compares
$2,829 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $83,794 |
| EliquisApixaban | 55 | $67,790 |
| JardianceEmpagliflozin | 62 | $56,179 |
| TrulicityDulaglutide | 30 | $38,582 |
| RybelsusSemaglutide | 15 | $35,136 |
| JanuviaSitagliptin Phosphate | 17 | $27,099 |
| XareltoRivaroxaban | 20 | $18,771 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $16,045 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $15,747 |
| MyrbetriqMirabegron | 11 | $13,541 |
| TradjentaLinagliptin | 16 | $12,501 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,874 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $10,477 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $5,553 |
| DuleraMometasone/Formoterol | 14 | $5,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $452 | $118,92978 claims |
| Boehringer IngelheimJardiance, Tradjenta | $648 | $68,68078 claims |
| PfizerEliquis | $27 | $67,79055 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $437 | $40,23144 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $66 | $37,39655 claims |
| Johnson & JohnsonXarelto | $415 | $18,77120 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $48 | $15,74712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Algonquin
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.